Abstract
Immune checkpoint inhibitors (ICIs) are becoming a standard therapy for non-small-cell lung cancer in the advanced stage. As these ICIs become widely available in clinical practice, immune-related adverse effects will become more common. Here we report a patient with lung adenocarcinoma who was treated with nivolumab and developed obstruction because of biliary inflammation. A 63-year-old Japanese man having lung adenocarcinoma with pleural dissemination complained of epigastric pain on the fifth cycle of nivolumab. Computed tomography showed wall thickening at the lower part of the bile duct and cholecystitis. Endoscopic retrograde cholangiopancreatography was repeatedly performed for drainage and stenting of the bile duct. Biopsies did not show obvious malignancy. Laboratory data on day 85 demonstrated grade 3 elevation of serum alkaline phosphatase, transaminase, and amylase levels. We initiated high-dose oral prednisone, resulting in gradual improvement of symptoms and laboratory data. Follow-up magnetic resonance cholangiopancreatography demonstrated no progression of duct obstruction, which confirmed the absence of biliary malignancy. Combined with results from previous reports, nivolumab may cause extrahepatic cholangitis.
Similar content being viewed by others
Abbreviations
- ALP:
-
Alkaline phosphatase
- ALT:
-
Alanine aminotransferase
- Amy:
-
Amylase
- AST:
-
Aspartate aminotransferase
- CT:
-
Computed tomography
- ENBD:
-
Endoscopic nasobiliary drainage
- ERCP:
-
Endoscopic retrograde cholangiopancreatography
- irAEs:
-
Immune-related adverse effects
- MRCP:
-
Magnetic resonance cholangiopancreatography
- NSCLC:
-
Non-small-cell lung carcinoma
- PD-1:
-
Programmed death receptor-1
- PD-L1:
-
Programmed death receptor ligand 1
References
Melosky B, Chu Q, Juergens R, Leighl N, McLeod D, Hirsh V (2016) Pointed progress in second-line advanced non-small-cell lung cancer: the rapidly evolving field of checkpoint inhibition. J Clin Oncol 34(14):1676–1688
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123–135
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627–1639
Ohara H, Okazaki K, Tsubouchi H, Inui K, Kawa S, Kamisawa T, Tazuma S, Uchida K, Hirano K, Yoshida H, Nishino T (2012) Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012. J Hepatobiliary Pancreat Sci 19(5):536–542
U.S.FDA. Administration (2014) OPDIVO (nivolumab) Injection label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125554lbl.pdf. Accessed 8 Apr 2017
Ikeuchi K, Okuma Y, Tabata T (2016) Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report. Lung Cancer 99:148–150
Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, Cauquil C, Chanson P, Collins M, Durrbach A, Ederhy S (2016) Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 27(4):559–574
Kawakami H, Tanizaki J, Tanaka K, Haratani K, Hayashi H, Takeda M, Kamata K, Takenaka M, Kimura M, Chikugo K, Sato T, Kudo M, Ito A, Nakagawa K (2017) Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs 35:529–536
Gelsomino F, Vitale G, D’Errico A, Bertuzzi C, Andreone P, Ardizzoni A (2017) Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol 28(3):671–672
Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM (2010) Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28(19):3167–3175
U.S.FDA. Administration (2014) KEYTRUDA (pembrolizumab) Injection label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf. Accessed 8 Apr 2017
Acknowledgement
The authors would like to thank Enago (https://www.enago.jp) for the English language review.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interests
The authors declare that they have no conflict of interest.
Funding sources
This report did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Ethical approval
For this type of study, formal consent is not required.
Informed consent
Informed consent was obtained from the patient presented in this article.
Rights and permissions
About this article
Cite this article
Kashima, J., Okuma, Y., Shimizuguchi, R. et al. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report. Cancer Immunol Immunother 67, 61–65 (2018). https://doi.org/10.1007/s00262-017-2062-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-017-2062-3